Compare Nerdwallet Inc (NRDS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nerdwallet Inc vs BIO-TECHNE Corp — how do they compare? Nerdwallet Inc trades at $9.41 (market cap $610.79M), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: BIO-TECHNE Corp is far larger — about 18.6× Nerdwallet Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.
| NRDS | TECH | |
|---|---|---|
Market Cap | $610.79M | $11.34B |
Sector | Financials | Health |
52-Week High | $15.93 | $72.48 |
52-Week Low | $7.58 | $43.31 |
Enterprise Value | $525.09M | $11.36B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRDS trades at $9.56, down 3.24% amid bearish technical signals, though fundamentals show strong improvement with revenue growing from $539M in 2022 to $837M in 2025 and net income turning positive. The stock appears undervalued with a P/E of 10.62 and P/S of 0.79, while analyst sentiment remains positive with 4 out of 6 ratings being Buy. Recent Q2 2026 earnings missed expectations but management highlights an inflection point in business operations.
The outlook is mixed: strong profitability metrics (93.5% gross margin, 18.16% ROE) and analyst price targets suggesting 27.9% upside support bullish case, but technical weakness and competitive pressures in credit card/search segments pose near-term risks. Execution on Q3 guidance and sustained cash flow generation will be critical for stock performance.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
